9.3252.30% ( +0.210 )
Delay Closed: Nov 16, 16:08:11Valuation
Current ValuationThe current P/E ratio is -8.87, above the reasonable range, cheaper than 7.35% of the time in the past 1 years, and the industry ranks 49/78, the industry Median -4.86.
-8.87xP/E
HK$9.33Stock price
HK$-1.05Earnings per share
-8.87xP/E
Stock priceHK$9.33Earnings per shareHK$-1.05
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -12.84x
- Typical range
- -31.34x–-10.40x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0152304456608
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -54.18x | 71.81% | HK$60.33B |
09688HKZAI LAB | -15.51x | 17.69% | HK$24.13B |
01877HKJUNSHI BIO | -31.64x | 83.59% | HK$14.54B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
07666HKMETIS TECHBIO-P | -24.60x | 96.67% | HK$10.01B |
06855HKASCENTAGE | -5.79x | 19.11% | HK$9.79B |
01952HKEVEREST MED | -147.04x | 326.79% | HK$9.13B |
09606HKDUALITYBIO-B | -5.35x | 85.35% | HK$8.86B |
02616HKCSTONE PHARMA-B | -17.06x | 1.09% | HK$8.23B |
02493HKMABWELL-B | -6.50x | -- | HK$7.95B |
02595HKGENFLEET-B | -4.86x | 66.07% | HK$7.36B |
06938HKRIBOLIFE-B | -34.82x | 29.56% | HK$6.80B |
09887HKLEADS BIOLABS-B | -21.52x | 3.57% | HK$6.62B |
02335HKMICOT PHARMA-B | -15.65x | 37.52% | HK$6.57B |
02171HKCARSGEN-B | -58.05x | 52.33% | HK$5.96B |
09966HKALPHAMAB-B | -26.96x | -- | HK$5.46B |
00775HKCKLIFE SCIENCES | -77.99x | -- | HK$5.05B |
02256HKABBISKO-B | -8.56x | 814.43% | HK$4.60B |
01672HKASCLETIS-B | -6.60x | 78.53% | HK$4.50B |
01779HKLONGBIO-B | -17.26x | -- | HK$4.30B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
